Navigation Links
Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
Date:6/2/2008

Landmark Study Shows Increased Survival for Non-Small Cell Lung Cancer

WASHINGTON, June 2 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) hailed the release of promising data from the pivotal Phase III First Line in Lung Cancer with Erbitux(R) (FLEX) Study. The data, presented at the American Society of Clinical Oncology (ASCO), showed a significant increase in overall survival in the first line treatment of patients with non-small cell lung cancer (NSCLC).

"This is very exciting news," said Laurie Fenton Ambrose, LCA President & CEO. "The FLEX data shows significant improvements in overall survival for a broad base of patients with no new safety concerns. This is so important to the lung cancer community because it will provide patients and doctors with another treatment option to consider when managing their diagnosis."

The FLEX study, conducted by Merck KGaA, enrolled more than 1,100 patients with Stage IIIb or IV NSCLC who had not previously received chemotherapy. The study included patients of all ages, regardless of their performance status (general well-being) who were diagnosed with all types of NSCLC. Erbitux(R) is a monoclonal antibody designed to inhibit the function of the epidermal growth factor receptor (EGFR). The major side effect from the drug is a rash.

Lung cancer is the leading cancer killer of both men and women in the United States with more than 162,000 deaths expected to occur in 2008, accounting for almost 30% of all cancer deaths.

"This is an important development," said David H. Johnson, MD, Deputy Director, Vanderbilt Ingram Cancer Center. "All lung cancer is notoriously difficult to treat. These results will further our understanding of NSCLC and provide a new standard of care for the lung cancer community."

For more information on the data please visit http://www.asco.org .

Lung Cancer Alliance (

SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that a ... catalogue: The Market for Medical Devices ... The European, Middle Eastern and African markets represent ... part of its coverage, this study: The Market ... EMEA medical device markets and estimates markets for ...
(Date:8/20/2014)... Aug 20, 2014 Reportlinker.com announces that ... its catalogue: Global Patient Scales Industry ... This report analyzes the worldwide markets for Patient ... Segments: Floor Scales, Infant & Baby Scales, Chair ... separate comprehensive analytics for the US, Canada, Japan, ...
(Date:8/20/2014)... MUMBAI , August 20, 2014 ... owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), ... studies of a novel clinical development candidate, GBR ... discovered and developed by the Glenmark Biologics Research ... . GBR 1302 is based on Glenmark,s ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
... Inc. (Nasdaq: BNVI ), a pharmaceutical company focused ... health and cancer, today announced that it had received the ... Guidance meeting that took place on November 8, 2010. In ... clinical development plan. "We had a very ...
... U.S.A. Inc., (TRL) announced today that it has entered into ... development of novel protein therapies for autoimmune diseases based on ... Anaphore will generate novel trivalent proteins called Atrimers ... inhibit targets of interest . The partnership will focus ...
Cached Medicine Technology:Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 2Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 3Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 4Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders 2Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders 3
(Date:8/20/2014)... of brain cells that act as a "sleep switch" ... and staying asleep, a new study suggests. In ... often results in nighttime confusion and wandering, according to ... Rush Memory and Aging Project, which includes nearly 1,000 ... followed until death, at which point their brains are ...
(Date:8/20/2014)... By Kathleen Doheny ... -- Breast reconstruction after a mastectomy has long been an ... percent of women choose it. "The most common reasons ... important, they weren,t interested in more surgery or they were ... Morrow, chief of breast surgery at Memorial Sloan Kettering Cancer ...
(Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
(Date:8/20/2014)... With 3943.8% growth, Connexion Point ranks number ... fastest growing companies. The Inc. 500 ranks Connexion Point 12th, ... Point is the #1 fastest growing company in Utah. , ... and its clients include four of the top 10 health ... and has offices and contact centers in Salt Lake City, ...
(Date:8/20/2014)... YORK, NY (August 20, 2014) Research from Columbia ... critical role in stomach cancer growth and that blocking ... an effective treatment for the disease. The study was ... in collaboration with Duan Chen, MD, PhD, in Norway ... Translational Medicine . , "Scientists have long observed that ...
Breaking Medicine News(10 mins):Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... the pioneer and largest provider of retail-based health care in the ... test at its 23 locations inside select CVS/pharmacy stores in the ... in partnership with Rapid Pathogen Screening, Inc (RPS). MinuteClinic hopes ... clinic locations in 25 states. , , The ...
... , ENCINITAS, Calif., Aug. 11 DRJ Group ... today announced a new awareness and fundraising initiative with the Arthritis ... portion of each Stopain purchase to support the Foundation,s mission to ... is issuing a just-released video - Stop Pain. Start Dancing ...
... , , NEW YORK, Aug. 11 ... bank has acquired Park Avenue Fertility, located in the heart of ... bank will be able to offer local services in both Los ... reproductive medicine. , , "California Cryobank has ...
... , , NEW YORK, Aug. ... a contract by ValueOptions(R), a behavioral health care company headquartered ... services for ValueOptions(R) at risk Plans, which cover approximately 1.5 ... Medicaid members that have other healthcare coverage, and recover overpayments ...
... , , , ... that many claim to value personal responsibility, yet the lack of ... less responsible than they take credit for being. , , ... While the decisions made by those running large corporations influenced the ...
... , TROY, Mich., Aug. 11 CareTech Solutions, Inc. ... inform a tion t echnology (IT) and ... provider for hospitals and health systems nationwide, announced today it has signed a three-year ... e gri s -health.com ), based in Oklahoma. , ...
Cached Medicine News:Health News:MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes 2Health News:MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes 3Health News:Photo: Stopain and the Arthritis Foundation Join Forces to Promote the Benefits of Staying Active 2Health News:Nation's Leading Sperm Bank Opens Branch in New York City 2Health News:ValueOptions(R) Awards Coordination of Benefits and Overpayment Services Contract to HMS 2Health News:Author Alison Stein Identifies Widespread Crisis in Personal Responsibility, Outlines Path to Solution in Reality 2Health News:CareTech Signs Three-Year Agreement to Provide Web Services to INTEGRIS Health's 13 Hospitals 2Health News:CareTech Signs Three-Year Agreement to Provide Web Services to INTEGRIS Health's 13 Hospitals 3
... Lipoprint System is a high resolution diagnostic test ... by other methods. The test procedure is simple ... hours. Any abnormal value is clearly flagged. A ... atherogenic, small dense LDL in red and the ...
... is the only control for ... patient synovial fluid samples performed ... is also an aid for ... indicate a pathological condition present ...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
... designed for point-of-care dipstick control. Its unique, ... problems and provides maximum portability ideal ... is the addition of creatinine and microalbumin. ... results for hCG for early pregnancy detection ...
Medicine Products: